Omnicell (OMCL) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: N/A
• Average Volume (3M): 400.61K
• Price to Earnings (P/E): 82.4
• Beta (1Y): 0.27
• Revenue Growth: 10.67%
• EPS Growth: N/A
• Country: US
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.51
• Shares Outstanding: 44,876,522
• 10 Day Avg. Volume: 420,823
• 30 Day Avg. Volume: 400,609
• PEG Ratio: -1.02
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 1.84
• P/FCF Ratio: 13.55
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 1.17
• Enterprise Value/Gross Profit: 2.67
• Enterprise Value/Ebitda: 11.71
• 1Y Price Target: $40.67
• Price Target Upside: 15.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: $37.00 ▲(5.35% Upside)

Omnicell's overall stock score reflects a stable financial position and strong technical momentum. The company's strategic initiatives and product adoption indicate positive momentum, but high valuation and profitability challenges weigh on the score. The earnings call provided a positive outlook, though tariff impacts and slower growth in certain areas present risks.

Positive Factors

Recurring Revenue Growth

The focus on recurring revenue through subscription models and platform expansion ensures stable, predictable income, enhancing long-term financial stability.

Product Innovation

Continuous product innovation strengthens competitive positioning and meets evolving customer needs, driving future revenue growth and market share.

Cybersecurity Certification

Achieving cybersecurity certification enhances trust and operational excellence, crucial for sustaining partnerships with healthcare providers concerned about data security.

Negative Factors

Revenue Decline

A decline in revenue indicates potential challenges in market demand or competitive pressures, which could impact long-term growth if not addressed.

Operational Efficiency

Low operational efficiency, as indicated by weak margins, suggests difficulties in cost management, which could hinder profitability and cash flow generation.

Tariff Impacts

Tariff impacts on profitability highlight external risks that could affect margins and financial performance if mitigation strategies are insufficient.

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc. is a healthcare technology company that specializes in medication management solutions and supply chain automation. Founded in 1992 and headquartered in Mountain View, California, Omnicell operates primarily in the healthcare sector, providing innovative products and services designed to improve patient safety, enhance operational efficiency, and streamline pharmacy and medication management processes. Its core offerings include automated medication dispensing systems, pharmacy management software, and inventory management solutions, which are utilized by hospitals, long-term care facilities, and outpatient pharmacies.

How the Company Makes Money

Omnicell generates revenue through multiple streams, primarily by selling its automated dispensing systems and software solutions to healthcare providers. The company earns a significant portion of its revenue from the sale of hardware, including automated medication dispensing units and robotic systems. In addition to hardware sales, Omnicell also offers software solutions, maintenance contracts, and services that enhance the operational capabilities of its clients, creating recurring revenue through subscription and service contracts. Furthermore, strategic partnerships with healthcare organizations and technology providers contribute to its earnings by expanding market reach and integrating its solutions into existing healthcare infrastructures. The combination of these revenue streams allows Omnicell to maintain a robust financial model, driven by ongoing demand for healthcare efficiency and safety improvements.

Omnicell Financial Statement Overview

Summary

Omnicell demonstrates a stable financial position with a strong balance sheet and positive cash flow trends. Revenue and profit margins are improving, but operational efficiency remains a challenge. The company is well-positioned with low leverage, but enhancing profitability and cash flow coverage could further strengthen its financial health.

Income Statement

Omnicell's income statement shows moderate performance with a gross profit margin of 43.7% and a net profit margin of 1.7% for TTM. The company has demonstrated revenue growth of 2.5% in the TTM period, recovering from a previous decline. However, the EBIT and EBITDA margins are relatively low, indicating potential challenges in operational efficiency.

Balance Sheet

The balance sheet reflects a strong equity position with a debt-to-equity ratio of 0.16, indicating low leverage and financial stability. The return on equity is modest at 1.6%, suggesting limited profitability from shareholders' equity. The equity ratio is healthy, supporting the company's financial resilience.

Cash Flow

Omnicell's cash flow statement shows positive trends with an 8.9% growth in free cash flow. The operating cash flow to net income ratio is 0.34, and the free cash flow to net income ratio is 0.73, indicating efficient cash generation relative to net income. However, there is room for improvement in cash flow coverage.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.11B	1.15B	1.30B	1.13B	892.21M
Gross Profit	516.04M	471.00M	499.93M	588.99M	554.65M	413.29M
EBITDA	117.75M	90.09M	60.69M	96.85M	174.44M	107.12M
Net Income	19.92M	12.53M	-20.37M	5.65M	77.85M	32.19M
Balance Sheet
Total Assets	1.95B	2.12B	2.23B	2.21B	2.14B	1.82B
Cash, Cash Equivalents and Short-Term Investments	180.05M	381.68M	467.97M	330.36M	349.05M	485.93M
Total Debt	194.89M	382.55M	614.09M	616.74M	528.06M	516.10M
Total Liabilities	727.70M	877.65M	1.04B	1.08B	995.81M	857.00M
Stockholders Equity	1.22B	1.24B	1.19B	1.13B	1.15B	967.50M
Cash Flow
Free Cash Flow	111.47M	151.26M	126.08M	17.04M	173.47M	131.00M
Operating Cash Flow	153.26M	187.72M	181.09M	77.78M	231.81M	185.87M
Investing Cash Flow	-59.51M	-52.79M	-55.02M	-58.67M	-412.50M	-279.87M
Financing Cash Flow	-461.84M	-235.58M	23.42M	-20.95M	47.36M	456.27M

Omnicell Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Positive. The current price of 35.12 is above the 20-day moving average (MA) of 33.37, above the 50-day MA of 31.94, and above the 200-day MA of 32.17, indicating a bullish trend. The MACD of 1.43 indicates Negative momentum. The RSI at 59.82 is Neutral, neither overbought nor oversold. The STOCH value of 63.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OMCL.

Omnicell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OMCL	69 Neutral	$1.58B	82.36	1.62%	―	10.67%	―
GDRX	65 Neutral	$1.01B	34.58	4.90%	―	1.30%	―
TXG	60 Neutral	$2.01B	―	-10.12%	―	1.92%	59.18%
CERT	58 Neutral	$1.33B	123.59	1.03%	―	11.47%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TDOC	48 Neutral	$1.23B	―	-15.42%	―	-2.37%	77.85%
EVH	45 Neutral	$466.49M	―	-13.63%	―	-16.65%	-71.92%

Omnicell Corporate Events

Omnicell’s Earnings Call: Growth Amid Challenges

Omnicell’s recent earnings call painted a picture of robust revenue growth and strategic success, despite some notable challenges. The sentiment expressed during the call was largely positive, driven by strong performance in point-of-care solutions and the OmniSphere platform. However, the company acknowledged hurdles such as declining earnings per share (EPS) and tariff impacts on profitability. Despite these issues, Omnicell’s strategic initiatives and product adoption suggest a positive trajectory.

Omnicell Surpasses Q3 2025 Financial Expectations

Omnicell, Inc. is a company that specializes in transforming pharmacy and nursing care delivery through innovative medication management solutions, operating primarily in the healthcare technology sector.

Omnicell Updates Bylaws for Enhanced Governance

On September 30, 2025, Omnicell, Inc.’s board of directors adopted the fourth amended and restated bylaws, effective immediately. These amendments enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, address matters related to Rule 14a-19 under the Exchange Act, clarify personal jurisdiction provisions, and make various updates, impacting the company’s governance and stakeholder engagement.

The most recent analyst rating on (OMCL) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.

Omnicell Appoints New CFO Baird Radford

Omnicell, Inc. announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer, effective August 26, 2025. Radford, with over 30 years of experience in healthcare and technology finance, succeeds Nchacha Etta, who will remain as an executive adviser until November 2025. This leadership change is part of Omnicell’s strategy to align its financial strategy with its innovation roadmap, enhancing its position as a digitally-enabled medication management technology company.

The most recent analyst rating on (OMCL) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.